2023/06/17 | 06:47:32
2023 Peripheral Nerve Society (PNS) Annual meeting

PNS 2023: Summary of Meeting Highlights and Takeaways – Future Directions

Kleopas A. Kleopa and Daniela Menichela- SPC co-Chairs

Content Disclaimer:  The suggestions listed below are that of the PNS Scientific Program Committee Co-Chairs & do not represent the opinions of the PNS Board, nor the Society as a whole.

1. Novel technologies and ideas have emerged to understand pathomechanisms at single cell level, genetic causes, create innovative models, and test therapeutics for neuropathies:

  • single cell RNAseq and spatial transcriptomics, lipidomics and bulk RNA-sequencing
  • innervated skin on a chip model
  • Organoid models of myelination
  • iPSCs
  • Long read sequencing and structural DNA variations

TO DO: These are currently limited to certain models and types of neuropathies. Need to be taken up by all SIGs, from bench to bedside, in a multidisciplinary approach to improve diagnosis and treatment of all neuropathies with clinical applications

2. Novel Imaging approaches and biomarkers, innovative trial design for peripheral nerves and neuromuscular system

  • FINEscope imaging of intraepidermal fibers
  • Novel ultrasound methods (Shear Wave Elastography Imaging, Photoacoustic Imaging, Artificial Intelligence)
  • Biomarkers (tau, NFL, imaging)
  • Sensitive clinical outcome measures
  • Complexity of trial design: patient selection, disease duration and activity

TO DO: Further validation of diagnostic accuracy across neuropathy types and against traditional invasive methods still needed. Longitudinal evaluations of biomarkers mostly lacking, natural history studies highly needed across neuropathies

3. Emerging new therapies for inherited and acquired neuropathies

  • New targets for therapeutic genome editing
  • Gene editing, gene silencing, gene replacement all applied to neuropathies
  • Viral and non-viral gene therapies progressing through pre-clinical development
  • Novel immunological therapies for autoimmune neuropathies
  • Novel drug-based approaches, some entering clinical trials

TO DO: Need to evaluate position of new therapies for each neuropathy type, bridge the gap to clinical translation, prioritize clinical trials, address rare neuropathies, develop guidelines for monitoring and treatment

Proposed goals for the PNS community to achieve the goals above

  • Enhance SIG interaction, incorporate new technologies (imaging, transcriptomics) into clinical trials for all PNs, harness them towards precision medicine, measure treatment response (biomarkers)
  • Facilitate exchange between basic scientists and clinicians, make available clinical material (tissues, cells) from well-characterized patients for molecular study, iPSCs across SIGs
  • Coordinated therapeutics development and evaluation, organize disease-focused treatment working groups to coordinate, prioritize, develop, and critically evaluate new treatments

Suggestions for implementation in the coming year

  • Create multidisciplinary working groups around the 3 basic topics (novel technologies, imaging tools, trial design) with representatives from all SIGs and between basic scientists and clinicians
  • Within each SIG establish neuropathy-type working groups for therapeutics development, assess current progress, identify priority areas, and advocate for translation, clarify position of each Tx in the clinic
  • Send survey after the meeting with questions to potential participants in each working group
  • SIGs to coordinate the establishment of the groups
  • Once established, working groups will set SMART goals and plan meetings
  • Each working group to present their SMART goals and report progress at 2024 PNS in Montreal!

Details Link

Back to listing
event-1 2024/07/13 | 00:34:25
中央社訊息服務20240523 16:37:35

Innovex 2024 工研院TREE主題館 展示多面向科技永續新創解決方案

亞洲指標新創展會 InnoVEX 主辦單位之一台北市電腦公會(TCA)表示,綠色科技永續營運是全球趨勢,Research and Markets研究報告指出,綠色科技和可持續性發展需求快速增加,預估全球市場將從2024年的286億美元,成長至2030年的1,349億美元,年複合成長率(CAGR)高達29.5%,因為全球企業正在透過採納綠色技術和可持續發展計劃,進行產業轉型,驅動力量包括日益提升的環境保護意識、嚴格的市場法規以及追求成本效益,因此企業必須把環保永續納入營運過程中,從供應鏈管理到產品開發無一不可避免。 TCA指出,InnoVEX 2024 科技新創雲集,本屆展覽透過「AI」、「ESG綠色科技」、「智慧移動」、「半導體應用」等四大主題展出內容,吸引許多符合主題之廠商參加。InnoVEX 2024共有23個國際辦事處、加速器、政府單位等主題館,將展出旗下熱門技術團隊與新創廠商。 由國立台灣大學光電所孫啟光教授實驗室之衍生新創團隊介觀生醫,致力於發展各項先進之超快雷射與極限光電工程技術,並應用於解決多項長期懸而未決之科學難題;更進而在工程上以影像之方式呈現,以提供目前臨床醫學、神經科學應用等所急需之奈米顯微術工具。

Read More
event-1 2023/12/30 | 06:53:02
2023/12/01 21:21:09 經濟日報 曹松清

創新創業激勵計畫頒獎3團隊獲創業傑出獎| 熱門亮點| 商情| 經濟日報

由國科會指導、國研院科政中心執行的「創新創業激勵計畫(From IP to IPO Program)」,透過為期6個月的培訓機制,協助學研擴散創新技術之影響力。 「創新創業激勵計畫」112年第二梯次決選暨頒獎典禮,今(1)日下午在臺灣科技新創基地(TTA)舉辦。由《台大介觀生醫團隊》、《成大基因體醫學中心》、《TPDH》等3組團隊榮獲「創業傑出獎」,並獲得企業贊助的100萬元創業基金,這不但是高技術認證之創業榮譽,更是新創學研團隊進入市場的重要基石。 該梯次學研團隊展現優秀的創新研發能力,並帶著熱忱進行各種研發,決心以科研技術來解決市場痛點,積極勇敢邁出創業第一步。第一階段篩選出40組優秀的學研團隊,在歷經6個月的培訓機制,共7組最具潛力的新創團隊進入決選,並由評審團針對市場趨勢、技術含量及創業決心等進行綜合評估,最終選出3組「創業傑出獎」得主。 國研院科政中心自2013年開始執行「創新創業激勵計畫」,推動至今已超過10年,積極發掘培育具競爭力的新創團隊與青年,深耕各領域的專業師資,並協助鏈結科學園區及國內外業師。為了將學研新創點子順利推向市場,於培訓期間提供早期商業化最重要的三大基礎定位:專利佈局、財務評估與獲利模式精準化等輔導,學研團隊亦於2次商業培訓營與5堂實務課程中融會貫通商化邏輯。 科政中心同時也提供平台線上媒合,以及全年無休輔導專線,致力成為學研團隊發展創新技術與創業第一哩路的最佳夥伴。本梯次歷經專業培訓的新創新星,亦於決選暨頒獎典禮上呈現技術實力與展示培訓成果。 「創新創業激勵計畫」推動至今共培育超過838組新創團隊,成立了403家公司,更帶動民間投入超過82.8億元的創業資金,有效鏈結早期學研新創與民間產業。國科會期許學研團隊的各式創新技術能促成臺灣產業良性循環並活絡國內市場,並勉勵團隊從創業初期即能以可規模化的技術進行國際布局,善用前瞻科學及跨域資源來解決全球性的問題,向全球展現臺灣新創的科技實力。

Read More
event-1 2023/06/17 | 06:47:32
2023 Peripheral Nerve Society (PNS) Annual meeting

PNS 2023: Summary of Meeting Highlights and Takeaways – Future Directions

Kleopas A. Kleopa and Daniela Menichela- SPC co-Chairs Content Disclaimer:  The suggestions listed below are that of the PNS Scientific Program Committee Co-Chairs & do not represent the opinions of the PNS Board, nor the Society as a whole. 1. Novel technologies and ideas have emerged to understand pathomechanisms at single ...

Read More
event-1 2023/08/19 | 06:37:14
Pathology News

Speeding up Intraoperative Tumor Assessment and Overcoming Limitations of Frozen Biopsy

Tumors of the brain and central nervous system can be fatal, and surgery is often required for their removal. To avoid disease recurrence, it is necessary to ensure that the tumor is completely removed. “While removing the tumor, a clinician often needs to look for any leftover tumor tissue,” Dr. ...

Read More

Request a quick quotation

Get Started Now